Natera
Trade Natera 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTRA
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).
NTRA Key Statistics
Stock Snapshot
Natera(NTRA) stock is priced at $276.28, giving the company a market capitalization of 39.57B. It carries a P/E multiple of -168.32.
As of 2026-07-02, Natera(NTRA) stock has fluctuated between $266.33 and $279.42. The current price stands at $276.28, placing the stock +3.7% above today's low and -1.1% off the high.
The Natera(NTRA)'s current trading volume is 1.86M, compared to an average daily volume of 2.19M.
During the past year, Natera(NTRA) stock moved between $131.81 at its lowest and $279.42 at its peak.
During the past year, Natera(NTRA) stock moved between $131.81 at its lowest and $279.42 at its peak.
NTRA News
...
(RTTNews) - Natera, Inc. (NTRA), a clinical genetic testing company, and Aveta Biomics, Inc., an immuno-oncology company, on Monday announced a partnership to s...
Over the last 7 days, the United States market has experienced a 2.5% drop, yet it remains up by 19% over the past year with earnings forecasted to grow by 18%...
Analyst ratings
88%
of 24 ratingsMore NTRA News
Guggenheim analyst Subbu Nambi raised the firm’s price target on Natera (NTRA) to $290 from $270 and keeps a Buy rating on the shares. The firm adjusted models...
Natera (NTRA) and Aveta Biomics announced a strategic partnership supporting AVTA 30-01, Aveta’s global Phase 3 registrational clinical trial evaluating APG-157...
Natera and Eledon Pharmaceuticals announced a partnership to use the Prospera test in a global Phase 3 kidney transplant trial. Prospera will serve as the excl...
Analyst Evie Koslosky from Goldman Sachs maintained a Hold rating on Natera and keeping the price target at $245.00. TipRanks' Prime Week Sale - 70% Off Unlock...
(RTTNews) - Cell-free DNA testing company Natera, Inc. (NTRA) and Eledon Pharmaceuticals, Inc. (ELDN) announced on Thursday that they have entered into a partne...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.